Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a nickel-free, nitric oxide-coated rhenium alloy frame and smaller delivery profile, aiming for less invasive procedures. The device is still investigational and not yet approved for commercial use. Boston Scientific may pay up to $3 billion more if clinical and regulatory milestones are met, aligning with its strategy to expand its cardiovascular portfolio. MiRus has also launched the STAR pivotal trial to evaluate the valve's safety and effectiveness in over 1,000 patients across various risk groups.
Boston Scientific announced a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase, acquiring about 30.4 million shares based on May 15 closing prices. This ASR is part of a larger $5 billion share repurchase authorization, lea...
Boston Scientific has invested $1.5 billion to acquire approximately 34% equity in MiRus LLC, a company developing innovative cardiovascular implants including the SIEGEL Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system. This i...
Boston Scientific's stock has dropped over 43% year-to-date, wiping out years of gains due to lowered guidance and weakness in key segments like WATCHMAN and Urology. Despite this, a new Buy rating has been initiated, citing achievable guidance after...
